Brief: Mereo Biopharma Receives FDA Fast Track Designation For Alvelestat For Treatment Of Alpha-1 Antitrypsin Deficiency (Aatd)-Associated Lung Disease
17/10/2022 12:15
Oct 17 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* MEREO BIOPHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR
ALVELESTAT FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
(AATD)-ASSOCIATED LUNG DISEASE
Source text for Eikon: ID:nGNX6JfT6Y
Further company coverage: MAH0y.F
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand